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Abstract
Background: Australia and New Zealand have the highest incidence rates of colorectal cancer worldwide. In Australia
there is significant unwarranted variation in colorectal cancer screening due to low uptake of the immunochemical
faecal occult blood test, poor identification of individuals at increased risk of colorectal cancer, and over-referral of
individuals at average risk for colonoscopy. Our pre-trial research has developed a novel Colorectal cancer RISk
Prediction (CRISP) tool, which could be used to implement precision screening in primary care. This paper describes
the protocol for a phase II multi-site individually randomised controlled trial of the CRISP tool in primary care.
Methods: This trial aims to test whether a standardised consultation using the CRISP tool in general practice (the CRISP
intervention) increases risk-appropriate colorectal cancer screening compared to control participants who receive
standardised information on cancer prevention. Patients between 50 and 74 years old, attending an appointment with
their general practitioner for any reason, will be invited into the trial. A total of 732 participants will be randomised to
intervention or control arms using a computer-generated allocation sequence stratified by general practice. The
primary outcome (risk-appropriate screening at 12 months) will be measured using baseline data for colorectal cancer
risk and objective health service data to measure screening behaviour. Secondary outcomes will include participant
cancer risk perception, anxiety, cancer worry, screening intentions and health service utilisation measured at 1, 6 and
12 months post randomisation.
Discussion: This trial tests a systematic approach to implementing risk-stratified colorectal cancer screening in primary
care, based on an individual’s absolute risk, using a state-of-the-art risk assessment tool. Trial results will be reported in 2020.
Trial registration: Australian and New Zealand Clinical Trial Registry, ACTRN12616001573448p. Registered on 14
November 2016.
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Background
Colorectal cancer is the third most common cancer in
men (746,000 cases in 2012, 10.0% of the total cancer
cases) and the second in women (614,000 cases in 2012,
9.2% of the total cases) worldwide. There is a wide geo-
graphical variation in incidence of colorectal cancer
worldwide, with the highest rates in Australia and New
Zealand and the lowest in Western Africa [1]. Internation-
ally, screening is recognised as an effective method to
reduce the burden of colorectal cancer. Randomised
controlled trials of faecal occult blood test (FOBT) screen-
ing have demonstrated a 15–33% reduction in colorectal
cancer mortality [2–4]. Despite this, few countries have an
organised screening programme, and those with highly
organised population-based screening often have a low
screening uptake [5].
Colorectal cancer screening in Australia
In Australia, biennial immunochemical FOBT (iFOBT)
screening from age 50 years has been shown to be
cost-effective with an estimated cost ranging from
AUD$17,192 to 53,883 per year of life saved [6]. In 2006,
the Australian government began the phased roll-out of a
population-based colorectal cancer screening programme
using the iFOBT. From 2020, the National Bowel Cancer
Screening Program (NBCSP) will be fully implemented, of-
fering biennial screening to all eligible people. The NBCSP
sends a free iFOBT kit in the mail to all Australians
between 50 and 74 years old for them to self-complete and
return for analysis. Positive test results are managed by the
participant’s nominated general practitioner who organises
a colonoscopic investigation. Participation rates in the
NBCSP remain low, with only 39% of the 2.6 million people
invited returning a completed kit [7]. According to the
Australian Commission on Safety and Quality in Health-
care report, almost 600,000 colonoscopies were performed
in 2013–14 [8] suggesting that some people may be having
colonoscopic screening instead of completing the NBCSP
screening kit.
Australian guidelines (both previous and recently up-
dated guidelines) recommend that colonoscopic screen-
ing should only be offered to individuals at increased
risk on the basis of their family history of colorectal can-
cer [9, 10]. In 2012, based on the 2005 Australian Guide-
lines risk criteria [10], it was estimated that for every 1
million Australians 50 years and older, 80,000 people at
average risk were being over-screened with colonoscopy,
while 29,000 people at increased risk were not having
the required colonoscopy [11, 12].
Risk-stratified screening
People are not at equal risk of colorectal cancer. While
the average population lifetime risk of colorectal cancer
is around 5%, there is a wide spectrum of risk with large
proportions of the population actually below or above
the “average” risk [13].
Colorectal cancer risk for the quarter of the population
with the highest contribution of risk factors is 20 times
greater than for those in the lowest quartile, and 90% of
colorectal cancer occurs in those in the upper half of the
population for these risk factors [13]. Australian guide-
lines recommend screening with an iFOBT for people at
“average and slightly increased risk” and colonoscopy for
those at “increased risk”. However, these guidelines rely
only on age and family history and are limited in their
ability to detect individuals at high risk [10]. Risk predic-
tion models can provide estimates of colorectal cancer
risk so that more expensive and higher risk preventive
strategies, such as colonoscopy, can be targeted at those
most likely to benefit [14, 15].
What is the difference between a cancer risk prediction
model and a cancer risk assessment tool?
Risk prediction models are mathematical algorithms
which combine demographic, clinical, lifestyle and gen-
etic factors to accurately determine future risk of devel-
oping colorectal cancer [16]. A risk assessment tool
applies a risk prediction model and presents risk infor-
mation in a way that will change the actions of patients
and clinicians. Identifying an accurate risk prediction
model is simply the first step. Translating a risk model
into clinical practice requires a risk assessment tool that
is easy to use in a clinic, can improve practice and is ac-
ceptable to clinicians and patients.
An Australian colorectal cancer risk prediction model
was developed and validated using data from the Colon
Cancer Family Registry (CCFR) and includes risk/pro-
tective factors: age, sex, body mass index (BMI), diet
(red meat and fruit), smoking (pack-years), previous
colorectal cancer screening (FOBT and/or colonoscopy),
polyp detection, use of medication (including non-ster-
oidal anti-inflammatories, hormone replacement ther-
apy, calcium) and first-degree relatives with colorectal/
endometrial/ovarian cancer and age of diagnosis [14].
The Colorectal cancer RISk Predictor (CRISP) tool is a
web-based risk assessment tool [17] which calculates an
individual’s absolute risk of developing colorectal cancer
(presented as 5-year and lifetime risk) (Fig. 1) based on
an analysis of the Colon Cancer Family Registry [18].
The CRISP tool presents the risk information using pre-
viously evaluated risk communication formats [19, 20],
and provides clinical decision support about recom-
mended screening (Fig. 2). A 2.5% 5-year absolute risk of
colorectal cancer was set as the threshold for switching
from recommending biennial FOBT testing to 5-yearly
colonoscopy. This threshold was chosen to be consistent
with the risk categories recommending colonoscopy in
the current National Health and Medical Research
Walker et al. Trials  (2018) 19:397 Page 2 of 14
Council (NHMRC) guidelines. The CRISP tool also iden-
tifies people with a family history suggestive of a rare
inherited cancer syndrome (e.g. Lynch syndrome) and
recommends referral to a family cancer clinic rather
than providing screening advice.
The development and evaluation of the CRISP tool has
been informed by the UK’s Medical Research Council
Framework for the design and evaluation of complex in-
terventions [21, 22]. The CRISP tool design was informed
by a qualitative study involving 14 GPs who used a proto-
type version of the CRISP tool in simulated consultations
[17]. The methods to communicate risk information were
tested using a randomised vignette study with patients in
general practice. This informed a selection of expected
frequency trees and comparative risk graphs as the pri-
mary method of risk communication for patients at aver-
age and increased risk respectively [20].
This protocol is for a multi-site, individually randomised
controlled trial to test a primary care-led model of
risk-stratified colorectal cancer screening, using the CRISP
tool. The aim is to increase iFOBT uptake and reduce in-
appropriate colonoscopic screening in average-risk people,
and to increase colonoscopic screening in people identi-
fied at higher risk. Our trial procedures were piloted in
two general practices involving 85 participants. The pilot
study demonstrated feasibility of the recruitment and
Fig. 1 Screenshot of the CRISP tool with an example of a data entry screen. CRISP Colorectal cancer RISk Prediction
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randomisation procedures, refined the content of the
CRISP consultation and confirmed acceptability of collect-
ing patient-reported outcome measures [23].
The study protocol adheres to the SPIRIT statement
(Additional file 1) [24].
Objectives
The primary objective of the CRISP trial is to determine
whether the effect of a standardised consultation using the
CRISP risk assessment tool in general practice, compared
with the provision of generic cancer prevention informa-
tion, increases the proportion of participants who undergo
risk-appropriate colorectal cancer screening; that is, com-
pletion of the right screening test (iFOBT or colonoscopy)
based on an individual’s absolute risk of colorectal cancer
and the Australian Guidelines at the time [10]. The sec-
ondary objectives are: (1) to test the CRISP tool compared
with generic cancer risk reduction information on partici-
pants’ level of colorectal cancer risk perception, general
anxiety, cancer worry and cancer screening intentions;
Fig. 2 Example of a patient report generated by the CRISP tool
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and (2) to evaluate the CRISP tool on health service util-
isation and healthcare costs.
Hypotheses
1. A standardised consultation using the CRISP tool in
general practice will increase risk-appropriate
screening compared with generic information about
cancer prevention at 12-month follow-up.
2. The CRISP tool will increase the accuracy of
participants’ risk perception and their intentions for
risk-appropriate screening without an adverse
increase in cancer-specific anxiety after 1-month,
6-month and 12-month follow-up.
Methods
Participants, interventions and outcomes
Study setting
This is a multi-site individually randomised controlled
trial (RCT) set in at least eight general practices (pri-
mary care practices) in Melbourne, Australia. General
practices are purposively sampled from VicRen, the
University of Melbourne practice-based research
network which includes at least 200 general practices
[25]. Practices are recruited from different areas in
Melbourne to maximise the sociodemographic diver-
sity of participants.
Participants are recruited from general practice wait-
ing rooms prior to an appointment with their GP. Gen-
eral practices are eligible if they have at least 1000 active
patients between 50 and 74 years old, at least three con-
senting doctors and a private room available for recruit-
ing for at least 3 days per week.
Before starting recruitment in each general practice,
the research team meet with the GPs and practice nurses
to ensure they understand the expected clinical action in
response to the CRISP tool-generated risk assessment
reports, including how to respond to the participants in
the control arm.
Participants
Eligible participants for the trial are aged between 50
and 74 years old, which is consistent with the target
population for the Australian NBCSP. Participants are
able to read and write English and competent to give in-
formed consent. Patients with a previous diagnosis of
colorectal cancer are excluded as the CRISP tool is only
designed for people who have never had colorectal can-
cer. Patients with recent rectal bleeding or inflammatory
bowel disease are excluded and referred for assessment
by their GP because they may require colonoscopy as a
diagnostic rather than screening procedure. Patients
with known Lynch syndrome, familial adenomatous
polyposis or any other specific genetic predisposition for
colorectal cancer, ascertained by a detailed family history
of colorectal and other cancers, are excluded/family his-
tory of colorectal and other cancers, are excluded.
Recruitment
Participants attending a GP consultation for any reason
are recruited directly from the waiting room of general
practices. Eligible patients between 50 and 74 years old,
identified by reception staff from the daily appointment
list, are approached consecutively in the waiting room
by a research assistant (RA). If the patient is interested
in the study and fulfils the initial criteria (age and
appointment with a consenting GP), the RA takes them
through to the CRISP research officer (RO) in a private
room. The RO will discuss the trial and determine their
eligibility. This method of recruitment and intervention
delivery is designed to maximise accrual and reduce re-
cruitment bias, a significant flaw in most of the previous
trials of cancer risk assessment tools (Fig. 3) [26].
If the patient is eligible and interested, the RO explains
the plain language statement and consents to the patient
(Additional file 2). The participant is given a signed copy
of the consent form for his/her records. The RO com-
pletes an online baseline questionnaire with the partici-
pant once he/she has consented to the study but prior to
randomisation. The baseline questionnaire captures a
specific clinic identification code and other response
data, and these data are embedded into a clickable link
at the conclusion of the survey. This link points to an-
other server which hosts randomisation software. Ran-
domisation is automated on completion of the online
baseline questionnaire.
Intervention arm
Delivery of the intervention occurs on the day of recruit-
ment prior to the participant’s consultation with their
GP. After completion of baseline data collection, those
randomised to the intervention arm have their baseline
data automatically uploaded into the CRISP tool. Using
the risk calculation and risk-specific screening recom-
mendations generated by the CRISP tool, the RO dis-
cusses the participant’s risk of colorectal cancer and
recommendations about appropriate colorectal cancer
screening using a standardised consultation script. A
print-out summarising the participant’s colorectal cancer
screening recommendations and risk is given to them to
discuss with their GP (Fig. 2). The CRISP tool also gen-
erates a report for the GP which is subsequently
uploaded into the participant’s electronic records. If the
participant is classified by the CRISP tool to be at aver-
age risk and is due for an iFOBT (i.e. has not completed
one in the previous 2 years), he/she is provided with a
free iFOBT kit and asked to discuss this with his/her
GP. The RO provides brief advice on how to complete
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Fig. 3 Trial flow chart (refer to Fig. 4 data collected at each time point)
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the iFOBT kit. Those at increased risk who require a re-
ferral for colonoscopy are advised to discuss this with
their GP. Participants who are given an iFOBT kit dur-
ing the CRISP consultation receive a reminder by text
message at 1 month to prompt them to complete their
kit. The intervention arm participants also receive gen-
eric information on how they can reduce their colorectal
cancer risk.
The core intervention is the CRISP consultation but
the other components are designed to increase
self-efficacy to complete the FOBT for those at average
risk as part of an overall complex intervention [21, 22].
Control arm
After completion of the online baseline data, participants
randomised to the control arm are automatically
directed to an electronic presentation of the Cancer
Council Victoria’s Cut Your Cancer Risk brochure [27].
The RO discusses this with the participant using a stan-
dardised consultation script. The focus of the consult-
ation involves explaining modifiable factors that can
reduce the cancer risk including lifestyle changes, and
brief information about the national cancer screening
programmes for breast, cervical and colorectal cancer.
This is designed as a credible attention control which
also increases engagement in the trial for control partici-
pants to minimise attrition. All participants receive a
hard copy of the brochure. Participants randomised to
the control arm continue to access health services as
“usual care”.
Random allocation, concealment mechanism and blinding
Random allocation of the participant to either the inter-
vention or control arm is automated on completion of
the online baseline questionnaire to ensure allocation
concealment. The random allocation sequence, stratified
by general practice, was computer-generated by our stat-
istician (PC) with a 1:1 allocation ratio using random
permuted block sizes of four, six and eight within each
stratum. This sequence is incorporated into the random-
isation software. Within each clinic (stratum), the ran-
domisation software allocates the randomisation code
sequentially and then redirects the browser to the CRISP
Web App if the participant is randomised to the inter-
vention arm, or to a series of screens with the Cancer
Council Victoria’s Cut Your Cancer Risk information
[27] if randomised to the control arm.
Data collected
Baseline data collected include: demographics (age, sex,
postcode, language spoken at home and country of birth,
marital status, highest education level attained) and clin-
ical variables (age, height, weight, number of first-degree
relatives with colorectal cancer and ages of diagnoses,
smoking history, current fruit and red meat consumption,
history of use of non-steroidal anti-inflammatory drugs,
current use of hormone replacement therapy (women
only) and calcium supplements, and history and clinical
outcomes of previous FOBT, colonoscopy including previ-
ous polyps) [15]. Additional baseline measures of CRC
risk perception [28, 29], generalised anxiety [30], cancer
worry [31, 32] and intention to screen [33] are also in-
cluded in the baseline questionnaire.
Health service use is tracked using data extracted from
the Australian Government Department of Health
Medicare Benefits Schedule (MBS) [34] that maintains
information about visits to healthcare providers and
diagnostic tests, the National Bowel Cancer Screening
data to access FOBT screening and the Victorian
Hospital Admitted Episodes Dataset (VAED) to access
privately funded colonoscopic screening.
Outcome measures
The primary outcome is the proportion of participants
who have had risk-appropriate colorectal cancer screen-
ing measured at 12-month follow-up. For participants in
the intervention arm, appropriateness of screening will
be determined by the CRISP tool and is based on the
participant’s 5-year absolute risk of colorectal cancer,
using the 2.5% threshold, and their concordance with
the recommended mode and frequency of screening. For
the participants in the control arm, family history and
previous screening data collected in the baseline ques-
tionnaire will be used to determine risk-appropriate
screening in accordance with National Guidelines at the
time of recruitment.
The CRISP tool was developed using the previous 2005
Australian guidelines which were revised in October 2017.
As our trial was already underway with more than 300
participants recruited, the Trial Steering Committee
agreed that it was not appropriate to change the recom-
mendations halfway through recruitment. Nonetheless,
the changes to the risk criteria in the revised guidelines
were relatively minor but their potential impact will be ex-
amined in a pre-planned sensitivity analysis (see later) [9].
Screening behaviour will be obtained for all of the par-
ticipants from the following sources: participant
self-report; data from GP records (results of FOBT and/
or colonoscopy); Medicare Benefits Schedule through
the Department of Human Services (for specific colon-
oscopy item numbers); the National Bowel Cancer
Screening Program; and the Victorian Admitted Epi-
sodes Dataset (for colonoscopies conducted in Victorian
public hospitals not captured by MBS data).
The data collection will be done systematically and we
will use a hierarchical approach to determine the final
screening behaviour with self-report at the bottom of the
hierarchy. Where possible, self-report will be validated
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from other data sources. The Steering Committee have
formed a clinical sub-committee to make decisions about
“appropriate screening” behaviour for discordant reported
screening behaviour from the multiple data sources.
Blinded clinical review will be conducted on a case-by-case
basis to reach consensus when there are discordant results.
Secondary outcomes measured at 1, 6 and 12 months
1. Risk perception: family history of colorectal and other
cancers, are excluded perceived risk, both absolute and
comparative, is measured using validated scales from
our previously published systematic reviews and
primary research on colorectal cancer risk [28, 29].
2. Generalised anxiety using the State-Trait Anxiety
Inventory (STAI) scale [30].
3. Cancer-specific anxiety using an established measure
applied extensively in cancer screening research, and
previously modified for colorectal cancer [31, 32].
4. Intentions to have an iFOBT and/or colonoscopy in
the next 3 months, based on items from the Theory
of Planned Behaviour and previous research [29, 33].
5. Clinical outcomes of screening tests (e.g. detection
of polyps and cancers), obtained from GP records
(Additional file 3).
Other secondary outcomes
6. Proportion of participants who have had risk-
appropriate screening measured after 5 years from
baseline.
7. Health service utilisation and healthcare costs
resulting from implementation of the CRISP tool.
Measurement timing
Colorectal cancer screening behaviour will be collected for a
maximum period of 4.5 years prior to recruitment (the max-
imum period for which historic Medicare Benefits Schedule
data can be requested) and 5 years from recruitment. The
timing, modality and results of any previous screening will
be used to determine the time interval and modality of
screening during the trial period to measure the appropriate
screening outcome. Screening data at 1 year after recruit-
ment will be used to determine the primary outcome.
The participant-completed outcome measures (self-re-
ported screening behaviour, risk perception, general anx-
iety, cancer worry and intention to screen) are captured
at baseline and 1, 6 and 12 months (Fig. 4).
Sample size and power calculation
Sample size calculations were initially based on previously
published rates of risk-appropriate screening [11, 12] and
a 6.5% prevalence of increased risk of colorectal cancer in
a primary care population [35]. Based on these data,
allowing for 10% attrition at 12-month follow-up, to
achieve 90% power with a two-sided 5% level of signifi-
cance, the sample size was calculated at 278 participants
per arm to detect, at a minimum, a 10% difference in the
percentage of risk-appropriate screening at 12 months be-
tween the intervention and control arms. Given the low
estimated rates of risk-appropriate screening, we consid-
ered several scenarios where the risk-appropriate screen-
ing at 12 months also increased in the control arm
(Table 1) and selected a more conservative sample size
that was achievable and practical. Using data from the
NBCSP [36] and data on the benefits and harms of colon-
oscopy [5, 37], an estimated 10% improvement in
risk-appropriate screening would be associated with the
following outcomes per 1 million people aged 50 and
older: 92,000 more faecal occult blood tests, 3000 fewer
colonoscopies and 55 fewer deaths.
Revised sample size: updated using baseline data
Recruitment started in May 2017 after ethics approval
was granted. In December 2017 it became clear that we
were recruiting faster than anticipated and were close to
reaching our initial target sample size. At the quarterly
Trial Steering Committee meeting it was decided to re-
view the sample size assumptions to ensure that the
study was adequately powered. We were concerned that
the percentage of individuals with risk-appropriate screen-
ing may be higher in the primary care population than had
been found in previous community-based studies [11, 12]
that had been conducted prior to the roll-out of the
NBCSP in 2006. Based on baseline survey and
self-reported colorectal cancer screening of the 397 partic-
ipants collected prior to randomisation, we conservatively
estimated that risk-appropriate screening of the trial popu-
lation at baseline was no greater than 25%. The Trial Steer-
ing Committee reviewed these data in February 2018 and
recommended to increase the sample size to 366 per arm
(allowing for 10% attrition over the 12 months) to ensure
that the study has at least 80% power to detect a minimum
of 10% difference in the percentage of risk-appropriate
screening at 12 months between the intervention and con-
trol arms, assuming that 25% of the control participants
receive risk-appropriate screening at 12 months.
Statistical methods
Baseline participant characteristics will be compared
between the two study arms using descriptive statistics to
assess for chance imbalance. The primary analysis will
compare the proportion of participants who have had
risk-appropriate colorectal cancer screening at 12 months
using logistic regression with the randomisation stratifica-
tion factor, general practice, as a covariate. The analysis
will be repeated for the risk-appropriate colorectal cancer
screening at 5 years as a secondary longer-term outcome.
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Comparisons between arms on continuous secondary out-
comes will use a linear mixed-effects model that includes
arm (intervention and control), general practice and time
(baseline, 1, 6 and 12 months) as fixed effects and individ-
uals treated as random effects, with two-way interactions
between study arm and time, except baseline where study
arm means will be constrained to be equal.
Comparisons between study arms on binary secondary
endpoints with repeated outcomes measures will be per-
formed using logistic regression, using generalised estimat-
ing equations with robust standard errors to allow for the
repeated outcome measures on individuals, with general
practice included as a covariate. All analyses will be con-
ducted in Stata 15 [38]. The estimated intervention effects
will be reported as the odds ratio for binary outcomes and
the difference in means between the intervention and
control arms for continuous outcomes. All estimates will
be reported with respective 95% confidence intervals and
p values. For the secondary continuous outcomes,
pre-specified adjustment for baseline outcome measure
will increase the precision of the estimated intervention ef-
fect and may adjust the intervention effect if there is im-
balance on this measure at baseline.
A sensitivity analysis will be performed on the primary
and secondary endpoints to adjust for additional
pre-specified baseline variables, for example age, sex and
family history of colorectal cancer, in the regression
models to explore whether the estimated intervention ef-
fect is affected by the potential for imbalance of these
confounders in the sample.
A sensitivity analysis will also be conducted to assess
the impact of using the revised 2017 Australian Colorectal
Fig. 4 Schedule of enrolment, interventions and assessments. Baseline risk factors include age, sex, height, weight, smoking, medications, dietary
habits and previous colorectal cancer screening
Table 1 Required samples sizes for three different scenarios of increases in risk-appropriate screening in the intervention arm
compared to the control arm, assuming rate of risk-appropriate screening of 1% and 25% at baseline and level of significance = 0.05
Scenario (intervention vs control) Absolute difference in
appropriate screening
Power Sample size per arm Sample size per arm
allowing for 10% attrition
10% improvement vs 0% 11% vs 1% 90% 117 130
10% improvement vs 2.5% 11% vs 3.5% 90% 250 278
10% improvement vs 5% 11% vs 6% 90% 652 725
10% improvement vs 0% 35% vs 25% 80% 329 366
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Screening guidelines on the proportion of participants
classified as having risk-appropriate colorectal cancer
screening at 12 months and 5 years. All randomised partici-
pants will be included in the analysis in their assigned study
arms in accordance with the intention-to-treat principle
[39]. Possible differential attrition will be assessed by
comparing baseline characteristics of those who withdraw
against those who remain in the study. Appropriate
methods for dealing with missing data will be detailed in
the statistical analysis plan and be informed by a blinded re-
view of the data. Sensitivity analysis will be used to assess
the robustness of the missing data assumption.
A health economic analysis will combine a within-trial
and modelled analysis of the cost-effectiveness of imple-
menting the CRISP tool. The within-trial analysis will
focus on the incremental cost per appropriately screened
individual for the CRISP tool versus usual care. The
modelled analysis will combine observed colorectal
cancer detection rates from the trial with data from the
published literature to investigate the longer-term
cost-effectiveness of the CRISP tool using an economic
model. Within-trial costs in the two study arms will be
estimated based on data observed from general practice,
MBS, the NBCSP and the VAED records. Mean esti-
mates of costs will be used and confidence intervals will
be generated by resampling (boot-strap) techniques.
Benefits in the modelled analysis will be assessed as
quality-adjusted life years (QALYs) by extrapolating the
observed cancer detection rates from the trial to
longer-term survival and adjusting them by published
quality of life (utility) weights. Results will be presented
in terms of the incremental cost-effectiveness ratio
(ICER) as a cost per case detected for the within-trial
period, and a cost/QALY gained for the modelled ana-
lysis. Sensitivity analyses will be conducted to test the
robustness of the results of the economic analysis to var-
iations in the underlying assumptions and inputs.
Data monitoring
Participant information, including their preferred
method for follow-up contact, will be automatically pop-
ulated into Research Electronic Data Capture (REDCap)
data management software from the baseline online
questionnaire [40]. Follow-up questionnaires will be
completed either via an emailed link to an online ques-
tionnaire, a paper questionnaire sent to the participant
or a computer-assisted telephone interview. If surveys
are not completed/returned within 2 weeks of being
sent, a research assistant blinded to study arm allocation
will telephone participants to remind them to complete
the survey and offer to complete the survey over the
phone. Participants will be contacted a maximum of
three times by telephone to complete the survey. All
information and data will be stored in password-protected
computers only accessible to the study team.
The CRISP trial data will be monitored by a dedicated
(and blinded) research assistant and overseen by the
Steering Committee and led by the Chief Investigator
(JDE). The Trial Steering Committee includes primary
care experts, gastroenterologists, epidemiologists, senior
research staff and a consumer who will meet quarterly
to monitor recruitment progress, address any problems
and ensure that the project is being conducted according
to protocol. The research assistant will monitor trial
processes and report complaints, harms and adverse
events to the Trial Steering Committee. Given that the
intervention is evidence based and participants are re-
quired to be under the duty of care of their GP, any ad-
verse events will be reported to the GP with the
participant’s permission. The most likely adverse event is
increase in cancer worry which will be monitored weekly
by the research assistant responsible for data monitoring.
If any participant answers “often” for at least three of the
six questions in the cancer worry scale questions or “al-
most all the time” for at least one of the cancer worry
scale questions, they will be contacted by the research
assistant who will advise them to follow this up with
their GP if they have ongoing concerns. Any adverse
events will be recorded (including relation to study, se-
verity, potential for the event to have been anticipated
and action taken) and reported to the Trial Steering
Committee. Serious adverse events will also be reported
to the university ethics committee.
Minimising contamination
To maximise the fidelity of the methods, ROs have
been trained using simulated consultations to deliver
both the CRISP and control consultations in a stan-
dardised way. Specific consultation scripts for the
intervention and control arms are used to minimise
the risk of contamination. A random 10% of trial
consultations is monitored through audiotaping and
reviewed by the research team to ensure fidelity to
the consultation scripts. To reduce participant con-
tamination bias, only one participant per household
will be invited into the trial (if known). To reduce
clinician contamination, GPs are advised of the trial
protocols, including having written flow charts to re-
mind them of their expected management of inter-
vention and control participants. GPs will not have
access to the CRISP tool.
There is a small risk that GPs’ awareness of colorectal
cancer screening will be raised during the trial, which
could alter their total number of referrals for iFOBT and
colonoscopy, but not on the risk-appropriateness of
these referrals. Control participant GP records will be
evaluated to measure the proportion of iFOBTs ordered
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by the GP within 2 weeks of recruitment as a proxy
measure of contamination.
Blinding
The nature of the intervention means that participants
cannot be blinded to their treatment allocation. GPs will
only be aware of participants allocated to the intervention
arm and will not be informed when a participant is allo-
cated to the control arm. The majority of follow-up ques-
tionnaires will be completed by participants online or via
post and those completed by telephone are done so with a
blinded researcher. For the extraction of health service
utilisation data, research staff will be blinded to allocation
assignment. All study analyses will be conducted by a stat-
istician blind to the participants’ study arm allocation;
study arm allocation will be coded as A or B when data
are extracted from the online databases and supplied to
the statistician, with the key for the intervention or con-
trol arm revealed after data are analysed and interpreted.
Investigators will also remain blind to the study arm allo-
cation when interpreting the results.
Process evaluation
The quantitative trial data will be supplemented by
qualitative semi-structured, in-depth interviews after
12 months to assess the impact and experience of under-
going colorectal cancer risk assessment in primary care.
A purposive sample of participants will be interviewed,
comprising people at increased and average risk in the
intervention arm with a range of age and gender. The
sample will include participants whose screening inten-
tions and behaviours were changed and participants
whose screening intentions remained unaltered by the
CRISP intervention. Approximately 20 people will be
sufficient to generate a full range of themes and perspec-
tives, and allow for theme saturation in key areas. Inter-
views will be undertaken by an experienced qualitative
researcher, and will be informed by a topic guide based
on relevant literature and revised based on emerging
findings from the iterative analytic process [35, 41].
Ethics and dissemination
The study protocol has been approved by The University
of Melbourne Human Research Ethics Committee
(HREC ID number 1647804). The Australian Depart-
ment of Human Services (Reference Number MI6113)
approved the collection of Medicare Benefits Scheme
and health service utilisation data for the purpose of
colorectal cancer screening, and the Victorian Depart-
ment of Health and Human Services approved collection
of VAED data for the same purposes. Important protocol
changes will be reported to the trial register and ethics
committees as necessary. Eligible patients will be
provided with a plain language statement outlining
important information about the study in addition to re-
ceiving a signed copy of the consent form.
Each participant will be given a unique identification
number and all information provided by them will re-
main confidential. All data are stored securely on Uni-
versity of Melbourne password-protected computers
within locked facilities as required by the University of
Melbourne Ethics Committee. Only investigators in-
cluded in the original ethics applications or subsequent
amendments have access to the identified dataset.
The results of the study will be presented at relevant
conferences and published in peer-reviewed journals as
per the CONSORT guidelines. The trial findings will be
disseminated to participants who have indicated their
wish to be informed of the results of the study. GP
clinics that have participated in the trial will be provided
with a community report and presented with the results
at a clinic meeting. The findings will be presented at
international meetings including those of the Inter-
national Cancer in Primary Care (Ca-PRI meeting) and
the Society for Academic Primary Care (UK), and also to
contributing research institutions including the Univer-
sities of Cambridge (UK) and Washington (St Louis,
MO, USA). The data including the statistical code will
not be available for public access.
Discussion
Pragmatic vs explanatory trials
The PRECIS framework recognises the continuum be-
tween pragmatic and explanatory trials [42]. Pragmatic
(or phase III) trials test interventions in real-world set-
tings and often represent the final phase of trialling an
intervention. Explanatory trials (also called phase II or
efficacy trials) are more appropriate for novel interven-
tions and aim to test whether an intervention, delivered
in an ideal way, might work. The CRISP tool is being
tested in an ideal way using trained researchers and
comparing it against a standardised comparison with the
understanding that if the CRISP tool cannot alter colo-
rectal cancer screening when applied in this ideal way,
then there is no chance of it working in the real world.
In the past, there have been many pragmatic trials in
primary care with negative findings conducted without a
prior phase II trial. These negative pragmatic trials can-
not say whether it was because the intervention itself
was poorly designed, whether it was poorly implemented
or whether the trial was poorly conducted. This is the
rationale for a phase II trial of this novel intervention. If
the CRISP tool demonstrates a moderate effect, this will
justify proceeding to a larger phase III pragmatic cluster
randomised trial. If the tool demonstrates a large benefi-
cial effect, the trial will inform a widespread implemen-
tation strategy instead [21].
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Individual vs cluster randomised controlled trials
The relative advantages and disadvantages of participant-
level versus practice-level randomisation were carefully
considered when planning this trial. Our systematic review
of previous RCTs of cancer risk assessment tools [26]
highlighted the major disadvantages of cluster randomised
trials, including recruitment bias and the inability to ob-
tain participant-reported outcomes in control practices
[32] and the significant additional costs of recruiting suffi-
cient practices to achieve power [43]. Based on previous
primary care research in a lung cancer screening study
(CHEST Trial), individual participant-level randomisation
was chosen [44].
Colorectal cancer is a major health problem for the
western world. Early detection through faecal occult
blood screening is a highly cost-effective strategy [6].
This trial tests a systematic approach to implementing
colorectal cancer screening in primary care so that the
right person receives the right test at the right time.
More significantly, it will test a novel and transformative
approach to precision cancer screening in primary care,
based on an individual’s absolute risk of a specific
cancer, using a state-of-the-art risk assessment tool. The
trial findings will be reported in late 2020.
Trial status
Protocol version 3 (27 September 2017); recruitment
start date 9 May 2017; projected recruitment completion
date 3 July 2018.
Additional files
Additional file 1: SPIRIT checklist. (DOC 135 kb)
Additional file 2: Informed consent materials. Plain language
statements and consent forms. (PDF 376 kb)
Additional file 3: Additional outcome variables. (DOCX 17 kb)
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